These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18931548)

  • 1. Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors.
    Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee GK; Lee KH
    Urol Int; 2008; 81(3):306-11. PubMed ID: 18931548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.
    Krabbe LM; Bagrodia A; Haddad AQ; Kapur P; Khalil D; Hynan LS; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
    J Urol; 2015 May; 193(5):1486-93. PubMed ID: 25451830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.
    Kang CH; Yu TJ; Hsieh HH; Yang JW; Shu K; Huang CC; Chiang PH; Shiue YL
    Cancer; 2003 Oct; 98(8):1620-6. PubMed ID: 14534877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of KI-67 proliferation index in transitional cell carcinoma of renal pelvis and ureter].
    Korneev IA
    Vopr Onkol; 2005; 51(2):211-5. PubMed ID: 16223003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy.
    Wang P; Luo JD; Wu WF; Wang S; Cai SL; Shen BH; Shi SF; Wei KX; Zhang ZG; Chen ZD
    Braz J Med Biol Res; 2007 Jul; 40(7):979-84. PubMed ID: 17653452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factors and oncogene products in transitional cell carcinoma.
    Nakanishi K; Kawai T; Suzuki M; Torikata C
    Mod Pathol; 1996 Mar; 9(3):292-7. PubMed ID: 8685230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers.
    Novara G; De Marco V; Dalpiaz O; Galfano A; Bouygues V; Gardiman M; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Int J Urol; 2009 Feb; 16(2):187-91. PubMed ID: 19054165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma.
    Cosentino M; Palou J; Gaya JM; Breda A; Rodriguez-Faba O; Villavicencio-Mavrich H
    World J Urol; 2013 Feb; 31(1):141-5. PubMed ID: 22552732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor.
    Palou J; Rodríguez-Rubio F; Huguet J; Segarra J; Ribal MJ; Alcaraz A; Villavicencio H
    J Urol; 2005 Sep; 174(3):859-61; discussion 861. PubMed ID: 16093970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
    Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
    Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel p53/p130 axis in bladder tumors.
    Mudryj M; Reay E; Beckett L; Dandekar S; deVere White R; Gandour-Edwards R
    Urology; 2007 Sep; 70(3):608-12. PubMed ID: 17905135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].
    San Miguel Fraile P; Antón Badiola I; Ortiz Rey JA; Alvarez Alvarez C; Fernández Costas A; Lago Fernández M; Pelaez Boismorand E; Zungri Telo E; De La Fuente Buceta A
    Actas Urol Esp; 2003 Sep; 27(8):587-93. PubMed ID: 14587233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma.
    Murta CB; Antunes AA; Dall'Oglio MF; Mosconi A; Leite KR; Srougi M
    Clinics (Sao Paulo); 2008 Apr; 63(2):223-8. PubMed ID: 18438577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Milenkovic-Petronic D; Vuksanovic A; Dragicevic D; Bumbasirevic U; Tulic C
    Int Urol Nephrol; 2011 Sep; 43(3):729-35. PubMed ID: 21350863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.